Friday, 17 Nov 2017

You are here

Orencia Approved for Use in Psoriatic Arthritis

On July 6 the U.S. Food and Drug Administration (FDA) approved ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis (PsA). Approval is for both intravenous and subcutaneous (SC) injection formulations. (citation source http://buff.ly/2t6itxn)

This is the third rheumatic disease indication for abatacept (ABA) as it was previously approved for use in rheumatoid arthritis (RA) and moderate to severe polyarticular juvenile idiopathic arthritis and may be used alone or with methotrexate (MTX)

The approval was based on results from two randomized, double-blind, placebo-controlled trials in which abatacept was shown to reduce disease activity in both TNF-naive and previously TNF-exposed PsA patients. The trials  included 594 adult patients. 

The ACR20 response at Week 24  favored ABA over placebo using IV ABA (47.5% versus 19.0% PBO) or SC ABA (39.4% versus 22.3%).  Modest effects on skin scores (compared to other approved agents) were also seen. 

The safety profile seen with PsA patients was as expected with no new safety signals. The approval comes with the warning that abatacept not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologics therapies.

Weight based dosing regimens (for both SC and IV forms) is the same as that suggested for RA.  Those receiving the subcutaneous injection once weekly can do so without the need of an intravenous loading dose.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Novartis Features Secukinumab Data at ACR 17

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Structural disease progression is a major concern for AS and PsA patients as it may prompt mobility loss - new data to provide further evidence on the efficacy of Cosentyx to reduce structural disease progression.

FDA Approves Simponi Aria for Psoriatic Arthritis and Ankylosing Spondylitis

Janssen Biotech, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).